BDRX
Biodexa Pharmaceuticals Plc
NASDAQ · Healthcare · Biotechnology · GB
$0.39
−14.36%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.43
From 52W high−99.11%
Volume516133.00
Market cap$1.64M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$0.43
From 52W high
−99.11%
Volume
516133.00
Market cap
$1.64M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
33.6
MomentumView details →
1D Return
−14.36%
YTD Return
−96.63%
SummaryUpdated Jun 1, 2026
Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) is a Belgian-based drug delivery technology company founded in 2000 and headquartered in Cardiff, United Kingdom. Originally known as Midatech Pharma plc, the company rebranded to Biodexa Pharmaceuticals in March 2023. The company went public in December 2015 and focuses on developing innovative bio-delivery and biodistribution technologies for medicines, operating internationally with a particular emphasis on treating challenging medical conditions including brain tumors and psychiatric disorders.
Similar companies
Latest newsMore news →
Biodexa Pharmaceuticals announced that 100 patients had enrolled in its registrational Phase 3 Serenta trial of eRapa for familial adenomatous polyposis.7d agoBiodexa Pharmaceuticals PLC CEO Stephen Stamp discussed the company's lead oral drug candidate eRapa for Familial Adenomatous Polyposis (FAP) in a fireside chat.27d agoBiodexa Pharmaceuticals PLC entered into a warrant exercise agreement with an existing accredited investor for the exercise of 2,204,218 outstanding warrants at $1.05 per ADS, raising approximately $2.3 million in gross proceeds.35d ago